Biologic agents in rheumatoid arthritis: temporal trend of incremental benefits.
作者信息
Messori Andrea, Maratea Dario, Fadda Valeria, Trippoli Sabrina
机构信息
HTA Unit, Area Vasta Centro Toscana, Regional Health System, Via Guimaraes 9-11, 59100 Prato, Italy.
出版信息
Ther Adv Musculoskelet Dis. 2012 Dec;4(6):423-4. doi: 10.1177/1759720X12461724.
Abstract
摘要
相似文献
1
Biologic agents in rheumatoid arthritis: temporal trend of incremental benefits.类风湿关节炎中的生物制剂：增量效益的时间趋势。
Ther Adv Musculoskelet Dis. 2012 Dec;4(6):423-4. doi: 10.1177/1759720X12461724.
2
Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review.类风湿关节炎患者使用生物制剂后严重感染的发生率：系统评价。
JBI Evid Synth. 2023 May 1;21(5):835-885. doi: 10.11124/JBIES-22-00048.
3
Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study.老年男性炎症性疾病患者中生物制剂的使用模式：一项以机构为中心、观察性的上市后研究。
Drugs Aging. 2009;26(7):607-15. doi: 10.2165/11316350-000000000-00000.
4
Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.三种静脉注射药物治疗的类风湿关节炎患者剂量递增的发生率及其对生物制剂成本的影响。
J Comp Eff Res. 2017 Nov;6(8):671-682. doi: 10.2217/cer-2016-0090. Epub 2017 Aug 9.
5
UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.利妥昔单抗用于对生物性改善病情抗风湿药反应欠佳的类风湿关节炎患者的英国成本效用分析。
Curr Med Res Opin. 2008 Sep;24(9):2639-50. doi: 10.1185/03007990802321683. Epub 2008 Aug 6.
6
Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.类风湿关节炎患者在生物制剂临床试验中的可推广性。
Arthritis Care Res (Hoboken). 2016 Oct;68(10):1478-88. doi: 10.1002/acr.22860. Epub 2016 Sep 16.
7
The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.在类风湿关节炎注册研究中，生物制剂使用对患者结局（疾病活动度、功能和疾病严重程度）的纵向影响。
Clin Rheumatol. 2019 Nov;38(11):3081-3092. doi: 10.1007/s10067-019-04649-4. Epub 2019 Jul 29.
8
Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.类风湿关节炎患者静脉血栓栓塞的风险：启动改善病情抗风湿药物治疗时的情况
Am J Med. 2015 May;128(5):539.e7-17. doi: 10.1016/j.amjmed.2014.11.025. Epub 2014 Dec 20.
9
Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.类风湿关节炎患者的治疗模式、生物制剂直接成本及直接医疗成本：基于日本全国索赔数据的真实世界分析
Clin Ther. 2016 Jun;38(6):1359-1375.e1. doi: 10.1016/j.clinthera.2016.03.022. Epub 2016 Apr 19.
10
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis.甲氨蝶呤治疗失败的类风湿关节炎患者早期使用原研生物制剂或其生物类似药的成本效益。
Adv Ther. 2019 Aug;36(8):2086-2095. doi: 10.1007/s12325-019-00986-7. Epub 2019 May 30.
本文引用的文献
1
Meta-analysis of observational studies to evaluate immediate outcomes after endarterectomy or stenting for carotid artery stenosis.评估颈动脉内膜切除术或支架置入术后近期疗效的观察性研究的Meta分析。
Ann Vasc Surg. 2012 Nov;26(8):1166-7. doi: 10.1016/j.avsg.2012.05.009.
2
The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials.生物制剂在类风湿关节炎进展损害中的作用：来自随机临床试验数据的间接比较。
Ther Adv Musculoskelet Dis. 2012 Aug;4(4):213-23. doi: 10.1177/1759720X12449082.
3
Immediate and late outcome of patients aged 80 years and older undergoing isolated aortic valve replacement: a systematic review and meta-analysis of 48 studies.80 岁及以上患者行单纯主动脉瓣置换术的即刻和远期结局：48 项研究的系统评价和荟萃分析。
Am Heart J. 2012 Mar;163(3):477-85. doi: 10.1016/j.ahj.2011.12.005.
4
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.复发缓解型多发性硬化症的治疗：通过网络荟萃分析总结当前信息。
Eur J Clin Pharmacol. 2012 Apr;68(4):441-8. doi: 10.1007/s00228-011-1141-1. Epub 2011 Nov 5.
Zotero 插件